Risk-stratified prostate cancer (PCa) screening, based on serum prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) scanning as a follow-up measure, is currently recommended by the European Union [1]. This evidence concerns the gene KLK3 and Familial prostate cancer.